| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
Product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Gross product sales |
|
$ |
85,624 |
|
$ |
56,322 |
|
$ |
225,508 |
|
$ |
143,728 |
Discounts and allowances |
|
|
(21,557) |
|
|
(17,395) |
|
|
(58,943) |
|
|
(45,348) |
Total product sales, net |
|
|
64,067 |
|
|
38,927 |
|
|
166,565 |
|
|
98,380 |
Revenues from collaborations: |
|
|
|
|
|
|
|
|
|
|
|
|
Release of cost share liability |
|
|
— |
|
|
— |
|
|
39,981 |
|
|
— |
License revenue |
|
|
— |
|
|
10,000 |
|
|
— |
|
|
10,000 |
Milestone revenue |
|
|
— |
|
|
— |
|
|
3,000 |
|
|
— |
Delivery of drug supplies, royalty and others |
|
|
5,395 |
|
|
6,380 |
|
|
14,934 |
|
|
13,302 |
Total revenues from collaborations |
|
|
5,395 |
|
|
16,380 |
|
|
57,915 |
|
|
23,302 |
Total revenues |
|
$ |
69,462 |
|
$ |
55,307 |
|
$ |
224,480 |
|
$ |
121,682 |
|
| Schedule of product revenue allowance and reserve categories |
The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2025 |
|
$ |
13,374 |
|
$ |
8,343 |
|
$ |
4,723 |
|
$ |
26,440 |
Provision related to current period sales |
|
|
40,399 |
|
|
14,261 |
|
|
1,921 |
|
|
56,581 |
Adjustment related to prior period sales |
|
|
(307) |
|
|
(1,287) |
|
|
(1,357) |
|
|
(2,951) |
Credit or payments made during the period |
|
|
(40,673) |
|
|
(8,950) |
|
|
(427) |
|
|
(50,050) |
Balance as of September 30, 2025 |
|
$ |
12,793 |
|
$ |
12,367 |
|
$ |
4,860 |
|
$ |
30,020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2024 |
|
$ |
8,236 |
|
$ |
3,517 |
|
$ |
3,931 |
|
$ |
15,684 |
Provision related to current period sales |
|
|
34,565 |
|
|
9,167 |
|
|
884 |
|
|
44,616 |
Credit or payments made during the period |
|
|
(31,363) |
|
|
(6,441) |
|
|
(304) |
|
|
(38,108) |
Balance as of September 30, 2024 |
|
$ |
11,438 |
|
$ |
6,243 |
|
$ |
4,511 |
|
$ |
22,192 |
|
| Schedule of revenues from product sales disaggregated by customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
McKesson Corporation |
|
|
48% |
|
|
43% |
|
|
39% |
|
|
44% |
Cencora, Inc. |
|
|
23% |
|
|
19% |
|
|
17% |
|
|
20% |
Optime Care, Inc. |
|
|
11% |
|
|
* |
|
|
* |
|
|
* |
Cardinal Health, Inc. |
|
|
10% |
|
|
* |
|
|
* |
|
|
15% |
Lilly |
|
|
— |
|
|
— |
|
|
18% |
|
|
— |
Kissei |
|
|
* |
|
|
23% |
|
|
* |
|
|
14% |
|